13 completed. 13 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 13 |
| Phase 1 | 5 | Completed 5 |
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies Acalabrutinib, Pembrolizumab - Follicular Lymphoma (FL), CLL | Phase 1 / Phase 2 | Completed | Acerta Pharma BV | 161 | 2015-02-20 | 2026-05-13 |
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL Lenalidomide - CLL, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Arbeitsgemeinschaft medikamentoese Tumortherapie | 12 | 2012-06-01 | 2016-05-26 |
| Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Eltrombopag - CLL, Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2010-11-03 | 2023-03-23 |
| Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Revlimid, Rituximab - Chronic Lymphocytic Leukemia, CLL | Phase 2 | Completed | University of California, San Diego | 30 | 2010-08-01 | 2024-08-15 |
| Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL) Ofatumumab/HDMP - CLL | Phase 2 | Completed | Januario Castro, M.D. | 21 | 2010-08-01 | 2018-05-08 |
| A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue Lenalidomide - Leukemia, CLL | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2008-11-01 | 2021-07-01 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
| Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older Lenalidomide - Leukemia, CLL | Phase 2 | Completed | M.D. Anderson Cancer Center | 61 | 2007-10-01 | 2018-08-21 |
| Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF - AML, ALL | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 25 | 2002-12-01 | 2016-07-18 |
| Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia Oblimerson sodium, G3139 - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Completed | Genta Incorporated | 40 | 2001-01-01 | 2009-11-13 |
| Allogeneic Transplantation From Related Haploidentical Donors non-myeloablative hematopoietic cell transplantation, Anti-Thymocyte Globulin, Cyclosporine - Blood Cancer, Leukemia | Phase 2 | Completed | Stanford University | 16 | 2000-08-01 | 2019-12-04 |
| Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Cyclophosphamide, fludarabine, cyclosporine - AML, ALL | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 25 | 1999-07-01 | 2017-04-06 |
Leukemia, Lymphocytic, Chronic, B-Cell (9) · Leukemia (7) · Hodgkin Disease (4) · Multiple Myeloma (4) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Neoplasms (3) · Anemia, Aplastic (2) · Lymphoma, Mantle-Cell (2) · Myeloproliferative Disorders (2) · Recurrence (2) · Blast Crisis (1) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Burkitt Lymphoma (1)
Hemic and Lymphatic Diseases (13) · Immune System Diseases (13) · Immunoproliferative Disorders (13) · Lymphatic Diseases (13) · Lymphoproliferative Disorders (13) · Neoplasms by Histologic Type (13) · Hematologic Diseases (12) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Chronic Disease (10) · Disease Attributes (10) · Neoplasms (10) · Leukemia, B-Cell (9) · Leukemia, Lymphoid (9) · Lymphoma (6)
Lenalidomide (4) · Cyclosporine (3) · Cyclophosphamide (2) · Granulocyte Colony-Stimulating Factor (2) · Rituximab (2) · fludarabine (2) · Acetaminophen (1) · Alemtuzumab (1) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · Capecitabine (1) · Diphenhydramine (1) · Gemcitabine (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Hydrocortisone (1)
M.D. Anderson Cancer Center (3) · Beth Israel Deaconess Medical Center (2) · Acerta Pharma BV (1) · Arbeitsgemeinschaft medikamentoese Tumortherapie (1) · Cyteir Therapeutics, Inc. (1) · Genta Incorporated (1) · Gilead Sciences (1) · Januario Castro, M.D. (1) · Stanford University (1) · University of California, San Diego (1)
United States (11) · Austria (1)
David E Avigan, MD (2) · David F McDermott, MD (2) · Thomas J Kipps, MD, PhD (2) · Alessandra Ferrajoli, M.D. (1) · Januario Castro, MD (1) · Markus Renschler, MD (1) · Robert Lowsky (1) · Sriram Yennurajalingam, MD (1) · William G. Wierda, MD, PHD, BS (1) · William Wegener, MD, PhD (1)
PMID 16186597, PMID 21173095, PMID 21725050, PMID 23801633, PMID 26389849, PMID 29358183